Evotec (NASDAQ:EVO) Shares Gap Up - Here's Why

Key Points

• Evotec shares opened higher, rising from a previous close of $1.89 to $1.95 before trading around $1.9550.
• Analyst sentiment remains mixed but leans toward Hold: MarketBeat reports an average rating of Hold and a consensus price target of $3.00, with recent downgrades from several firms.
• The stock’s 50-day and 200-day moving averages stand at $2.27 and $2.71, respectively, while hedge funds and institutional investors own approximately 5.81% of the company.

Evotec AG (NASDAQ:EVO - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $1.89, but opened at $1.95. Evotec shares last traded at $1.9550, with a volume of 10,420 shares.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on EVO shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Evotec in a report on Tuesday, July 21st. Wall Street Zen cut shares of Evotec from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. TD Cowen downgraded shares of Evotec from a "buy" rating to a "hold" rating and set a $2.00 price target for the company. in a research report on Wednesday, July 15th. Berenberg Bank lowered shares of Evotec from a "buy" rating to a "hold" rating in a research note on Thursday, July 16th. Finally, HC Wainwright decreased their price target on shares of Evotec from $7.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Evotec currently has an average rating of "Hold" and a consensus price target of $3.00.

Evotec Stock Performance

The business has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.71. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62.

Hedge Funds Weigh In On Evotec

Several hedge funds and other institutional investors have recently modified their holdings of the business. ABC Arbitrage SA raised its holdings in Evotec by 319.7% in the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company's stock valued at $1,707,000 after acquiring an additional 422,230 shares during the last quarter. Marshall Wace LLP purchased a new position in Evotec in the 4th quarter worth approximately $40,000. HRT Financial LP acquired a new position in shares of Evotec during the 4th quarter worth approximately $72,000. Goldman Sachs Group Inc. acquired a new position in shares of Evotec during the 4th quarter worth approximately $110,000. Finally, BNP Paribas Financial Markets grew its position in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock valued at $50,000 after purchasing an additional 4,600 shares in the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source